Ratings by Wolfe Research (Rudy Li)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/26/2026 | Harmony Biosciences Holdings Inc. | HRMY | New Coverage | Outperform (N/A) |
38.95 (41.25) |
5.91% | Details | |
| 7/29/2026 | uniQure BV | QURE | Upgrade | Outperform (Peerperform) |
36.66 (47.86) |
30.55% | Details | |
| 7/27/2026 | MapLight Therapeutics | MPLT | Maintain | Outperform (N/A) |
|
Details | ||
| 7/7/2026 | Compass Pathways | CMPS | Maintain | Outperform (N/A) |
|
Details | ||
| 7/7/2026 | LB Pharmaceuticals Inc | LBRX | New Coverage | Outperform (N/A) |
33.41 (47.10) |
40.98% | Details | |
| 5/22/2026 | Alto Neuroscience | ANRO | New Coverage | Outperform (N/A) |
21.54 (35.20) |
63.42% | Details | |
| 5/22/2026 | Compass Pathways | CMPS | New Coverage | Outperform (N/A) |
11.59 (13.24) |
14.24% | Details | |
| 5/22/2026 | Immunic Inc. | IMUX | New Coverage | Outperform (N/A) |
12.30 (14.58) |
18.54% | Details | |
| 3/31/2026 | Centessa Pharmaceuticals | CNTA | Downgrade | Peerperform (Outperform) |
27.58 (40.50) |
46.85% | Details | |
| 2/24/2026 | uniQure BV | QURE | New Coverage | Peerperform (N/A) |
23.43 (36.66) |
56.47% | Details | |
| 2/24/2026 | Stoke Therapeutics | STOK | New Coverage | Outperform (N/A) |
34.29 (30.89) |
-9.92% | Details | |
| 2/24/2026 | Xenon Pharmaceuticals | XENE | New Coverage | Outperform (N/A) |
42.23 (60.00) |
42.08% | Details | |
| 2/24/2026 | Axsome Therapeutics | AXSM | New Coverage | Outperform (N/A) |
183.72 (202.83) |
10.4% | Details | |
| 2/24/2026 | Neurocrine Bio. | NBIX | New Coverage | Outperform (N/A) |
128.63 (156.76) |
21.87% | Details | |
| 2/24/2026 | Praxis Precision Medicines Inc. | PRAX | New Coverage | Outperform (N/A) |
335.28 (353.44) |
5.42% | Details | |
| 2/24/2026 | Acadia Pharmaceuticals | ACAD | New Coverage | Outperform (N/A) |
23.99 (28.89) |
20.43% | Details | |
| 2/24/2026 | Denali Therapeutics Inc. | DNLI | New Coverage | Peerperform (N/A) |
20.19 (23.27) |
15.26% | Details | |
| 2/24/2026 | Alkermes | ALKS | New Coverage | Outperform (N/A) |
31.91 (47.20) |
47.92% | Details | |
| 2/24/2026 | Centessa Pharmaceuticals | CNTA | New Coverage | Outperform (N/A) |
24.50 (27.58) |
12.57% | Details | |
| 2/23/2026 | Definium Therapeutics Inc | DFTX | New Coverage | Outperform (N/A) |
17.13 (38.50) |
124.75% | Details |
